XNAS · GALT
+0.00% · +$0.0000 · Vol Not reported
Market closed · last close shown
Galectin Therapeutics Inc.

Galectin Therapeutics Inc.

PHARMACEUTICAL PREPARATIONS
$3.68
Card
Relationship Map

Veridion Score

BETAHIGH CONF · 6/6 factorsMethodology
GALT
Galectin Therapeutics Inc.
Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

58/ 100
Veridion Score
NEUTRAL · HIGH confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6/6 factors with data · Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is GALT moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading GALT catalysts
About Galectin Therapeutics Inc.
PHARMACEUTICAL PREPARATIONS
Listed since
2002
Employees
9
Country
US

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$3.68
Last session
Day high
$3.68
Last session
Day low
$3.68
Last session
Previous close
$3.68
52W high
$6.51
-43.47% from high
52W low
$2.08
36% of range
Market cap
$371.1M
EPS
$-0.4700
Beta
0.33
Shares out
100.8M
Avg volume
471.5K
VWAP
$3.68
Last session
Price history computed in-house
1W
+4.84%
1M
+6.05%
3M
+31.90%
1Y
-10.24%
YTD
-11.54%
SMA 50 $3.67 · above
SMA 200 $3.51 · above
52W position 36%

GALT overview

Veridion Score
58
Registered · 2026-08-21
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around GALT.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading GALT Form 4 filings
Public disclosures

Congress activity in GALT

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for GALT in the cached public ledger.

Federal contracts

GALT contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for GALT in this window.
Lobbying spend

GALT lobbying filings, year to date.

Registered lobbying filings matched to Galectin Therapeutics Inc..

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for GALT in this window.
Loading news for GALT
Analyst ratings
Sovereign unlock shows live analyst consensus for GALT.
Options
Sovereign unlock shows live options positioning for GALT.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.